Concepedia

Author

P. C. Waldmeier

Novartis (Switzerland)

Also Known As

P C Waldmeier, P Waldmeier, P. C. WALDMEIER, P. C. Waldmeier, P. WALDMEIER, P. Waldmeier, P.C Waldmeier, P.C. WALDMEIER, P.C. Waldmeier, PETER C. WALDMEIER

197

Publications

6.4K

Citations

45

H-Index

106

Concepts

All Affiliations

Novartis (Switzerland)University of Basel
PC

About

P. C. Waldmeier is an author at Novartis (Switzerland) specializing in medicine, neuropharmacology, and neuroscience.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

37

87

3.7K

2

Social Sciences

28

54

2.4K

3

Natural Sciences

9

9

388

4

Engineering

6

6

164

5

Health Sciences

6

6

208

P. C. Waldmeier

×

107

Publications

5K

Citations

41

H-Index

YearCitations

Inhibition of the Mitochondrial Permeability Transition by the Nonimmunosuppressive Cyclosporin Derivative NIM811

P. C. Waldmeier, J.-J. Feldtrauer, Ting Qian,

Molecular Pharmacology

2002

285

Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 and R-(−)-Deprenyl

Eddy A. Kragten, Isabelle Lalande, Kaspar Zimmermann,

Journal of Biological Chemistry

1998

208

Specific γ‐hydroxybutyrate‐binding sites but loss of pharmacological effects of γ‐hydroxybutyrate in GABA<sub>B(1)</sub>‐deficient mice

Klemens Kaupmann, John F. Cryan, Petrine Wellendorph,

European Journal of Neuroscience

2003

184

Serotonin-dopamine interactions in the nigrostriatal system

P. C. Waldmeier, A. Delini‐Stula

European Journal of Pharmacology

1979

171

Alteration of central alpha2- and beta-adrenergic receptors in the rat after DSP-4, a selective noradrenergic neurotoxin

D. J. Dooley, H. Bittiger, Kathleen Hauser,

Neuroscience

1983

144

Preferential deamination of dopamine by an A type monoamine oxidase in rat brain

P. C. Waldmeier, A. Delini‐Stula, L. Ma�tre

Naunyn-Schmiedeberg s Archives of Pharmacology

1976

142

The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain-Derived Mitochondria

Magnus J. Hansson, Gustav Mattiasson, Roland Månsson,

Journal of Bioenergetics and Biomembranes

2004

137

Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters

P. C. Waldmeier, P. A. Baumann, Peter Wicki,

Neurology

1995

131

Transgenic Activation of Ras in Neurons Promotes Hypertrophy and Protects from Lesion-Induced Degeneration

Rolf Heumann, Christoph G. Goemans, Daniela Bartsch,

The Journal of Cell Biology

2000

126

A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

Vanita Chopra, Jonathan H. Fox, Greg Lieberman,

Proceedings of the National Academy of Sciences

2007

109

Page 1